GLSI RSI Chart
Last 7 days
2.9%
Last 30 days
8.4%
Last 90 days
25.9%
Trailing 12 Months
22.7%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 01, 2024 | patel snehal | bought | 57,240 | 19.08 | 3,000 | ceo and cfo |
Mar 22, 2024 | patel snehal | bought | 49,950 | 19.98 | 2,500 | ceo and cfo |
Mar 20, 2024 | patel snehal | bought | 26,520 | 17.68 | 1,500 | ceo and cfo |
Mar 05, 2024 | patel snehal | bought | 43,715 | 12.49 | 3,500 | ceo and cfo |
Mar 04, 2024 | patel snehal | bought | 53,423 | 13.03 | 4,100 | ceo and cfo |
Feb 16, 2024 | patel snehal | bought | 120,528 | 11.16 | 10,800 | ceo and cfo |
Feb 15, 2024 | patel snehal | bought | 140,589 | 11.07 | 12,700 | ceo and cfo |
Nov 10, 2023 | patel snehal | bought | 50,837 | 10.1675 | 5,000 | ceo and cfo |
Nov 03, 2023 | patel snehal | bought | 31,885 | 9.11 | 3,500 | ceo and cfo |
Oct 27, 2023 | thompson jaye | bought | 4,285 | 8.57 | 500 | vp clinical reg affairs |
Which funds bought or sold GLSI recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | JANE STREET GROUP, LLC | added | 47.39 | 264,269 | 411,602 | -% |
May 15, 2024 | GOLDMAN SACHS GROUP INC | new | - | 827,610 | 827,610 | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | reduced | -63.09 | -4,539 | 10,568 | -% |
May 15, 2024 | Royal Bank of Canada | reduced | -41.67 | - | - | -% |
May 15, 2024 | STATE STREET CORP | unchanged | - | 122,479 | 259,260 | -% |
May 15, 2024 | 683 Capital Management, LLC | sold off | -100 | -206,234 | - | -% |
May 15, 2024 | MILLENNIUM MANAGEMENT LLC | added | 454 | 1,151,300 | 1,272,390 | -% |
May 15, 2024 | MORGAN STANLEY | added | 2,125 | 121,281 | 124,227 | -% |
May 15, 2024 | AMERIPRISE FINANCIAL INC | sold off | -100 | -564,372 | - | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | added | 16.38 | 61,424 | 112,362 | -% |
Unveiling Greenwich LifeSciences, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Greenwich LifeSciences, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Greenwich LifeSciences, Inc. News
Balance Sheet | |||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2018Q4 |
Assets | -23.6% | 7.00 | 9.00 | 11.00 | 12.00 | 13.00 | 16.00 | 17.00 | 20.00 | 27.00 | 29.00 | 30.00 | 30.00 | 29.00 | 6.00 | - | - | - | - |
Current Assets | - | - | - | - | - | - | - | - | - | - | 29.00 | 30.00 | 30.00 | 29.00 | 6.00 | - | - | 0.00 | 0.00 |
Cash Equivalents | -23.6% | 7.00 | 9.00 | 11.00 | 12.00 | 13.00 | 16.00 | 17.00 | 20.00 | 27.00 | 29.00 | 30.00 | 30.00 | 29.00 | 6.00 | - | - | 0.00 | 0.00 |
Liabilities | -1.0% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 1.00 | 1.00 | 2.00 | 2.00 | 1.00 | 1.00 | 10.00 |
Current Liabilities | -1.0% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 1.00 | 1.00 | 2.00 | - | - | 1.00 | 1.00 |
Shareholder's Equity | -24.3% | 7.00 | 9.00 | 11.00 | 12.00 | 13.00 | 15.00 | 17.00 | 20.00 | 27.00 | 28.00 | 29.00 | 30.00 | 28.00 | 5.00 | - | - | - | - |
Retained Earnings | -5.8% | -50.36 | -47.62 | -45.23 | -43.60 | -41.47 | -38.68 | -36.36 | -35.62 | -33.65 | -31.29 | -30.42 | -29.67 | -29.08 | -27.93 | - | - | -27.21 | -23.79 |
Additional Paid-In Capital | 1.1% | 57.00 | 56.00 | 56.00 | 55.00 | 55.00 | 54.00 | 53.00 | 55.00 | 60.00 | 60.00 | 60.00 | 59.00 | 57.00 | 33.00 | - | - | 26.00 | 14.00 |
Shares Outstanding | 0% | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | - | - | - | - | - | - |
Float | - | - | - | 57.00 | - | - | - | 49.00 | - | - | - | 171 | - | - | - | - | - | - | - |
Cashflow (Quarterly) | |||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2019Q4 | 2019Q3 | 2018Q4 |
Cashflow From Operations | -19.6% | -2,154 | -1,800 | -966 | -1,556 | -2,170 | -1,549 | -532 | -1,947 | -2,264 | -894 | -604 | -528 | - | - | - | - |
Share Based Compensation | 0% | 595 | 595 | 595 | 595 | 595 | 760 | 225 | 165 | 165 | 165 | 165 | 165 | 165 | - | - | - |
Cashflow From Financing | - | - | - | - | - | - | - | -2,022 | -5,513 | 563 | - | - | 2,273 | 23,599 | - | - | - |
Buy Backs | - | - | - | - | - | - | - | 2,023 | 5,514 | - | - | - | - | - | - | - | - |
Statements of Operations - USD ($) | 12 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Income Statement [Abstract] | ||
Revenue | ||
Operating expenses | ||
Research and development | 7,698,622 | 6,475,668 |
General and administrative | 1,629,244 | 1,564,586 |
Total operating expenses | 9,327,866 | 8,040,254 |
Loss from operations | (9,327,866) | (8,040,254) |
Interest income | 436,063 | 215,017 |
Net loss | $ (8,891,803) | $ (7,825,237) |
Per share information: | ||
Net loss per common share, basic | $ (0.69) | $ (0.61) |
Net loss per common share, diluted | $ (0.69) | $ (0.61) |
Weighted average common shares outstanding, basic | 12,848,165 | 12,913,848 |
Weighted average common shares outstanding, diluted | 12,848,165 | 12,913,848 |
Balance Sheets - USD ($) | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets | ||
Cash | $ 6,989,424 | $ 13,468,026 |
Acquired patents, net | 5,391 | 9,003 |
Total assets | 6,994,815 | 13,477,029 |
Current liabilities | ||
Accounts payable & accrued interest | 256,317 | 220,845 |
Unreimbursed expenses | 38,089 | 42,060 |
Total current liabilities | 294,406 | 262,905 |
Total liabilities | 294,406 | 262,905 |
Stockholders’ equity | ||
Common stock, $0.001 par value; 100,000,000 shares authorized; 12,848,165 shares issued and outstanding as of December 31, 2023 and 2022 | 12,848 | 12,848 |
Additional paid-in capital | 57,052,130 | 54,674,042 |
Accumulated deficit | (50,364,569) | (41,472,766) |
Total stockholders’ equity | 6,700,409 | 13,214,124 |
Total liabilities and stockholders’ equity | $ 6,994,815 | $ 13,477,029 |